Abstracts tagged "Myopathies"

Abstract Number: 0958 • ACR Convergence 2020
Tocilizumab in Myositis: Results of a Phase IIb Double-Blind Randomized Controlled Trial
Rohit Aggarwal¹, Howard Rockette², Swamy Venturupalli³, Galina Marder⁴, Mazen Dimachkie⁵, David Gazeley⁶, Floranne C. Ernste⁷, Leslie Crofford⁸, Siamak Moghadam-Kia⁹, Diane Koontz⁹, Lei Zhu¹ and Chester Oddis¹⁰, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³Cedars Sinai Medical Center, Los Angeles, ⁴Northwell, New York, ⁵Univeristy of Kansas, Medical Center, Kansas City, KS, ⁶Medical College of Wisconsin, Wauwatosa, WI, ⁷Mayo Clinic, Rochester, ⁸Vanderbilt University Medical Center, Nashville, ⁹University of Pittsburgh Medical Center, Pittsburgh, PA, ¹⁰Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: To assess the efficacy and tolerability of tocilizumab (anti-IL-6R, TCZ), in a multi-center, randomized, double blind, placebo-controlled trial in refractory adult dermatomyositis (DM) and…
Abstract Number: 1097 • ACR Convergence 2020
Immunophenotypic Characterization of Myeloid Derived Supressor Cells (MDSCs) and Their Relationship to the Clinical Characteristics of Patients with Inflammatory Myopathies
Hector Culebro¹, Jose Torres-Ruiz², Fabiola Cassiano Quezada¹ and Alfredo Perez Fragoso¹, ¹INCMNSZ, MEXICO, Mexico, ²NIAMS, National Institute of Health, Bethesda
Background/Purpose: Myeloid derived suppressor cells (MDSCs) including their granulocyte (Gr-MDSCs) and monocyte (Mo-MDSCs) subtypes constitute a cellular subset with potent immune regulatory capacity. An augmented…
Abstract Number: 0995 • ACR Convergence 2020
Jo-1-Binding B Cells Undergo Limited Class-Switching but Are Biased Towards Autoreactive-Prone and Memory B Cell Subsets in Anti-histidyl-tRNA Synthetase Syndrome
Jennifer Young-Glazer¹, Alberto Cisneros², Erin Wilfong¹, Scott Smith¹, Leslie J. Crofford¹ and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbit University Medical Center, Nashville, TN
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
Abstract Number: 1098 • ACR Convergence 2020
Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis
Iago Pinal-Fernandez¹, Katherine Pak², Albert Gil-Vila³, Andres Baucells⁴, Benjamin Plotz⁵, Maria Casal-Dominguez⁶, Assia Derfoul⁷, Maria Angeles Martinez⁴, Albert Selva-O'Callaghan³, Sara Sabbagh⁸, Frederick W. Miller¹, Lisa G. Rider⁹, Lisa Christopher-Stine¹⁰ and Andrew Mammen⁶, ¹National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Vall d’Hebron Hospital, Barcelona, Spain, ⁴Sant Pau Hospital, Barcelona, Spain, ⁵Division of Rheumatology, New York University Langone Health, New York, NY, ⁶NIH, Bethesda, MD, ⁷NIAMS, NIH, Bethesda, ⁸Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Washington, DC, ⁹Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.Methods: In this longitudinal cohort study, anti-cortactin autoantibody tiers were…
Abstract Number: 1057 • ACR Convergence 2020
Earlier Cancer Diagnosis After Idiopathic Inflammatory Myopathy Onset Is Associated with Improved Long Term Survival – Results from Four European Cohorts
Alexander Oldroyd¹, Paul New², Janine Lamb¹, William Ollier¹, Robert Cooper², Kuberacka Mariampillai³, Olivier Benveniste³, Jiří Vencovský⁴, Heřman Mann⁵, Zoltan Griger⁶, Melinda Nagy-Vincze⁶, Katalin Dankó⁶ and Hector Chinoy⁷, ¹University of Manchester, Manchester, United Kingdom, ²University of Liverpool, Liverpool, United Kingdom, ³Sorbonne Université, Paris, France, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶University of Debrecen, Debrecen, Hungary, ⁷The University of Manchester, Manchester, United Kingdom
Background/Purpose: The idiopathic inflammatory myopathies (IIMs) are strongly associated with the development of clinically detectable cancer. Cancer screening has therefore been advocated in newly diagnosed…
Abstract Number: 1060 • ACR Convergence 2020
B-cell-rich Inflammatory Myopathies in Adults: Striking Association with Connective Tissue Diseases
Pat Korathanakhun¹, Océane Landon-Cardinal², Valérie Leclair³, Benjamin Ellezam⁴, Alain Meyer⁵, Josiane Bourré-Tessier², Anne-Marie Mansour⁶, Sandrine Larue⁷, François Grand'Maison⁷, Rami Massie⁸, Matthieu Le Page⁹, Catherine Isabelle⁷, Nathalie Routhier⁶, Flavie Roy¹⁰, Minoru Satoh¹¹, Marvin Fritzler¹², Jean-Luc Senécal², Yves Troyanov¹³, Marie Hudson³, Jason Karamchandani¹⁴ and Erin O'Ferrall⁸, ¹Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ²Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ³Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ⁴Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada, ⁵Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ⁶Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada, ⁷Hôpital Charles-Lemoyne, Longueuil, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Centre hospitalier de Lanaudière, Saint-Charles-Borromée, QC, Canada, ¹⁰Uiversité de Montréal, Montreal, QC, Canada, ¹¹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ¹⁴Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada
Background/Purpose: Myositis with significant B-cell infiltrates on muscle biopsy has scarcely been described in adults. Radke (2018) found B cells in adult dermatomyositis (DM) and…
Abstract Number: 1061 • ACR Convergence 2020
Daily Myositis Symptom Changes Collected via a Smartphone-Based App Are Associated with Flare Occurrence – Providing Evidence of Potential Digital Biomarkers
Alexander Oldroyd¹, Belay Yimer², Max Little³, William Dixon² and Hector Chinoy⁴, ¹University of Manchester, Manchester, United Kingdom, ²Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴The University of Manchester, Manchester, United Kingdom
Background/Purpose: The concept of idiopathic inflammatory myopathy (IIM) flare is widely used, although no consensus definition exists. Studies have demonstrated the feasibility and utility of…
Abstract Number: 1062 • ACR Convergence 2020
Dermatomyositis: A Dermatology-Rheumatology Clinic Retrospective Analysis
Burak Elkiran¹, Mahroo Tajalli², Terrence M. Vance³, Abrar A. Qureshi⁴ and Anthony M. Reginato⁵, ¹Department of Medicine, Division of Rheumatology; Warren Alpert Medical School of Brown University, BOSTON, ²Department of Dermatology, Warren Alpert Medical School of Brown University, PROVIDENCE, ³Department of Epidemiology, Warren Alpert Medical School of Brown University, PROVIDENCE, ⁴Department of Dermatology, Warren Alpert Medical School of Brown University, BOSTON, ⁵Department of Medicine, Division of Rheumatology, Warren Alpert Medical School of Brown University, Boston, MA
Background/Purpose: Dermatomyositis (DM) can be categorized into two major subtypes: clinically amyopathic dermatomyositis (CADM) and classic dermatomyositis (CDM). In this study, we aimed to identify characteristics…
Abstract Number: 1064 • ACR Convergence 2020
Anti-SMN Autoantibodies Are Associated with Systemic Sclerosis Small Bowel Involvement in anti-U1RNP Positive Autoimmune Myositis
Caroline Vo¹, Océane Landon-Cardinal², Alexandra Albert³, Alain Meyer⁴, Valérie Leclair⁵, Josiane Bourré-Tessier², Sabrina Hoa², Eric Rich¹, Jean-Richard Goulet¹, Benjamin Ellezam⁶, Maude Bouchard-Marmen⁷, Martial Koenig⁸, Geneviève Gyger⁵, Ira N. Targoff⁹, Marie Hudson⁵, Minoru Satoh¹⁰, Marvin Fritzler¹¹, Yves Troyanov¹² and Jean-Luc Senécal², ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ³Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada, ⁴Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁵Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ⁶Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada, ⁷Division of Rheumatology, Centre Hospitalier de l’Université Laval, Department of Medicine, Université Laval, Québec, QC, Canada, ⁸Division of Internal Medicine, Centre hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹²Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada
Background/Purpose: The survival of motor neuron (SMN)/gemin proteins are components of a multifunctional protein complex that plays an essential role in RNA metabolism. SMN is…
Abstract Number: 1069 • ACR Convergence 2020
Scleromyositis Is Associated with Nailfold Capillary Abnormalities Compared to Immune-Mediated Necrotizing Myopathy
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Martial Koenig⁴, Alain Meyer⁵, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Isabelle Ferdinand⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Benjamin Ellezam¹¹, Jean-Luc Senécal¹, Marie Hudson² and Geneviève Gyger², ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Division of Internal Medicine, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁵Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁶Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis associated with features of systemic sclerosis (SSc) and characterized by prominent vasculopathic features on ultrastructural…
Abstract Number: 1070 • ACR Convergence 2020
Scleromyositis Is Associated with Distinct Muscle Vasculopathic Features
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Alain Meyer⁴, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Valérie Nadon⁵, Julie Drouin⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Jean-Luc Senécal¹, Marie Hudson² and Benjamin Ellezam¹¹, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁵Division of Rheumatology, Hôpital Notre-Dame, Montreal, Québec, Canada, Montréal, QC, Canada, ⁶Division of Rheumatology, Centre hospitalier régional de Trois-Rivières, Trois-Rivières, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis (AIM) associated with features of systemic sclerosis (SSc). Muscle biopsy studies are sparse and have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].